Endonovo Therapeutics (OTCMKTS:ENDV) and Scpharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
This table compares Endonovo Therapeutics and Scpharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Endonovo Therapeutics and Scpharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Endonovo Therapeutics||$80,000.00||35.18||-$6.44 million||N/A||N/A|
Endonovo Therapeutics has higher revenue and earnings than Scpharmaceuticals.
Insider and Institutional Ownership
40.7% of Scpharmaceuticals shares are owned by institutional investors. 5.6% of Endonovo Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Scpharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Endonovo Therapeutics and Scpharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Scpharmaceuticals has a consensus price target of $9.00, suggesting a potential upside of 102.25%. Given Scpharmaceuticals’ higher possible upside, analysts plainly believe Scpharmaceuticals is more favorable than Endonovo Therapeutics.
Risk & Volatility
Endonovo Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Scpharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. develops non-invasive electrocuetical devices for regenerative medicine. It is developing Electroceutical Therapy for the treatment of pain and post-surgical edema with a concentration on cosmetic surgeries, including breast augmentation, reduction and reconstruction surgery, rhinoplasty, and liposuction procedures. The company was incorporated in 2008 and is headquartered in Woodland Hills, California.
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Endonovo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endonovo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.